Your browser doesn't support javascript.
loading
Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics.
Delgado-Jiménez, Juan F; Segovia-Cubero, Javier; Almenar-Bonet, Luis; de Juan-Bagudá, Javier; Lara-Padrón, Antonio; García-Pinilla, José Manuel; Bonilla-Palomas, Juan Luis; López-Fernández, Silvia; Mirabet-Pérez, Sonia; Gómez-Otero, Inés; Castro-Fernández, Antonio; Díaz-Molina, Beatriz; Goirigolzarri-Artaza, Josebe; Rincón-Díaz, Luis Miguel; Pascual-Figal, Domingo Andrés; Anguita-Sánchez, Manuel; Muñiz, Javier; Crespo-Leiro, María G.
Afiliação
  • Delgado-Jiménez JF; Instituto de Investigación y Servicio de Cardiología del Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
  • Segovia-Cubero J; Centro de Investigación Biomédica En Red Cardiovascular (CIBERCV), 28029 Madrid, Spain.
  • Almenar-Bonet L; Centro de Investigación Biomédica En Red Cardiovascular (CIBERCV), 28029 Madrid, Spain.
  • de Juan-Bagudá J; Servicio de Cardiología, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain.
  • Lara-Padrón A; Centro de Investigación Biomédica En Red Cardiovascular (CIBERCV), 28029 Madrid, Spain.
  • García-Pinilla JM; Servicio de Cardiología, Hospital Universitario La Fe, 46026 Valencia, Spain.
  • Bonilla-Palomas JL; Instituto de Investigación y Servicio de Cardiología del Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
  • López-Fernández S; Centro de Investigación Biomédica En Red Cardiovascular (CIBERCV), 28029 Madrid, Spain.
  • Mirabet-Pérez S; Servicio de Cardiología, Hospital Universitario de Canarias, 38320 Santa Cruz de Tenerife, Spain.
  • Gómez-Otero I; Centro de Investigación Biomédica En Red Cardiovascular (CIBERCV), 28029 Madrid, Spain.
  • Castro-Fernández A; Servicio de Cardiología, International Business Information Management Association, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain.
  • Díaz-Molina B; Servicio de Cardiología, Hospital San Juan de la Cruz, Úbeda, 23400 Jaen, Spain.
  • Goirigolzarri-Artaza J; Servicio de Cardiología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
  • Rincón-Díaz LM; Centro de Investigación Biomédica En Red Cardiovascular (CIBERCV), 28029 Madrid, Spain.
  • Pascual-Figal DA; Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Anguita-Sánchez M; Centro de Investigación Biomédica En Red Cardiovascular (CIBERCV), 28029 Madrid, Spain.
  • Muñiz J; Servicio de Cardiología, Complexo Hospitalario Universitario de Santiago de Compostela, 15706 A Coruña, Spain.
  • Crespo-Leiro MG; Servicio de Cardiología, Hospital Universitario Virgen de la Macarena, 41009 Seville, Spain.
J Clin Med ; 11(5)2022 Feb 22.
Article em En | MEDLINE | ID: mdl-35268260
ABSTRACT
Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a negative impact on prognosis. The objective of the present study was to estimate the prevalence of hyperkalaemia in outpatients with HFrEF and its impact on achieving optimal medical treatment. For this purpose, a multicentre, prospective, and observational study was carried out on consecutive HFrEF patients who were monitored as outpatients in heart failure (HF) units and who, in the opinion of their doctor, received optimal medical treatment. A total of 565 HFrEF patients were included from 16 specialised HF units. The mean age was 66 ± 12 years, 78% were male, 45% had an ischemic cause, 39% had atrial fibrillation, 43% were diabetic, 42% had a glomerular filtration rate < 60 mL/min/1.7 m2, and the mean left ventricular ejection fraction was 31 ± 7%. Treatment at the study entry included 76% on diuretics, 13% on ivabradine, 7% on digoxin, 18.9% on angiotensin-conversing enzyme inhibitors (ACEi), 11.3% on angiotensin receptors blockers (ARBs), 63.8% on angiotensin-neprilysin inhibitors (ARNi), 78.5% on mineralocorticoid receptor antagonists (MRAs), and 92.9% on beta-blockers. Potassium levels in the baseline analysis were ≤5 mEq/L = 80.5%, 5.1−5.4 mEq/L = 13.8%, 5.5−5.9 mEq/L = 4.6%, and ≥6 mEq/L = 1.06%. Hyperkalaemia was the reason for not prescribing or reaching the target dose of an MRAs in 34.8% and 12.5% of patients, respectively. The impact of hyperkalaemia on not prescribing or dropping below the target dose in relation to ACEi, ARBs, and ARNi was significantly less. In conclusion, hyperkalaemia is a frequent problem in the management of patients with HFrEF and a limiting factor in the optimisation of medical treatment.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article